Today: 9 April 2026
Consumer Cyclical Stocks wobble into Monday as Tesla drags XLY and jobs report looms
4 January 2026
2 mins read

Consumer Cyclical Stocks wobble into Monday as Tesla drags XLY and jobs report looms

NEW YORK, January 4, 2026, 13:55 ET — Market closed

  • The Consumer Discretionary Select Sector SPDR ETF (XLY) ended Friday down 0.9% at $118.35.
  • Tesla slid 2.6% and Amazon fell 1.9%, pressuring the consumer cyclical group.
  • Investors’ next test is the U.S. jobs report on Jan. 9, followed by CPI inflation data on Jan. 13.

The Consumer Discretionary Select Sector SPDR ETF, a widely followed proxy for consumer cyclical stocks, ended Friday down 0.9% at $118.35 as Tesla and Amazon fell.

Consumer cyclical stocks—companies tied to discretionary spending on items like cars and home furnishings—often swing with shifts in jobs and interest-rate expectations. That sensitivity matters heading into the first full trading week of 2026, with key U.S. data set to reset the market’s view on growth and rate cuts. Reuters

“The market is looking for direction,” Matthew Maley, chief market strategist at Miller Tabak, said in a Reuters interview. The labor-market report due Jan. 9 is the near-term focal point, after the Federal Reserve cut rates at each of its last three meetings of 2025 and left investors debating how much easing is left this year. Reuters

Tesla’s slide on Friday followed the company’s release of fourth-quarter production and deliveries. Tesla said it delivered 418,227 vehicles in the October–December period and 1,636,129 vehicles in 2025, and it will report quarterly results after the close on Jan. 28. Tesla Investor Relations

In autos, demand pressures are not confined to Tesla. Rivian said 2025 deliveries fell to 42,247 vehicles and it will report results after markets close on Feb. 12, a reminder that higher-priced EV demand has stayed under scrutiny since U.S. tax credits ended in late 2025. Reuters

Elsewhere in the consumer cyclical space, tariff news offered a counterweight to the EV drag. The White House said President Donald Trump signed a proclamation delaying planned tariff increases on upholstered furniture, kitchen cabinets and vanities for another year; Wayfair, Williams-Sonoma and RH ended Friday up about 6%, 5% and nearly 8%, respectively, Reuters reported. Reuters

Technically, XLY traded between $117.71 and $120.41 in Friday’s session, levels traders often treat as near-term markers for support and resistance. A break above $120 in early trade on Monday would put the sector back on firmer ground after the late-2025 wobble, while a retest of Friday’s low would keep pressure on retailers and automakers.

But the downside scenario is straightforward: a weak jobs report can stoke recession fears and hit discretionary spending expectations, while a hotter inflation print can push yields higher and pressure interest-rate-sensitive stocks. Investors are also watching for policy surprises, including tariff-related headlines that can quickly change cost assumptions for import-heavy retailers. Reuters

The macro calendar is set to move markets quickly. Reuters reported the U.S. consumer price index is due Jan. 13, and Fed funds futures—derivatives that reflect investors’ expectations for the policy rate—indicate little chance of a cut at the Fed’s late-January meeting and roughly a 50% probability of a quarter-point reduction in March. Reuters

For consumer cyclicals, traders will start with Friday’s payrolls report on Jan. 9, then shift to CPI on Jan. 13 and Tesla’s Jan. 28 results for a read on demand and margins in one of the sector’s bellwethers. Reuters

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:14 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Berkshire Hathaway stock: OxyChem deal closes as investors size up the Abel era
Previous Story

Berkshire Hathaway stock: OxyChem deal closes as investors size up the Abel era

Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus
Next Story

Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus

Go toTop